AN2 Therapeutics Inc.

8.16+0.4100+5.29%Vol 32.88K1Y Perf -
Jul 1st, 2022 16:00 DELAYED
BID3.20 ASK11.54
Open7.68 Previous Close7.75
Pre-Market- After-Market-
 - -  - -%
Target Price
24.50 
Analyst Rating
Strong Buy 1.00
Potential %
200.25 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.67 
Earnings Rating
Market Cap158.32M 
Earnings Date
9th Aug 2022
Alpha-0.04 Standard Deviation0.05
Beta-0.88 

Today's Price Range

7.418.73

52W Range

6.8823.58

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-6.74%
1 Month
-47.08%
3 Months
-48.32%
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANTX8.160.41005.29
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.52-2.98-473.08
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.44
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume32.88K
Shares Outstanding19.40K
Shares Float9.99M
Trades Count699
Dollar Volume259.06K
Avg. Volume93.05K
Avg. Weekly Volume117.98K
Avg. Monthly Volume90.24K
Avg. Quarterly Volume70.92K

AN2 Therapeutics Inc. (NASDAQ: ANTX) stock closed at 8.16 per share at the end of the most recent trading day (a 5.29% change compared to the prior day closing price) with a volume of 32.88K shares and market capitalization of 158.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. AN2 Therapeutics Inc. CEO is .

The one-year performance of AN2 Therapeutics Inc. stock is %, while year-to-date (YTD) performance is %. ANTX stock has a five-year performance of %. Its 52-week range is between 6.8789 and 23.58, which gives ANTX stock a 52-week price range ratio of 7.67%

AN2 Therapeutics Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 1.47, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -23.41%, a ROC of -24.52% and a ROE of -24.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AN2 Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.44 for the next earnings report. AN2 Therapeutics Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for AN2 Therapeutics Inc. is Strong Buy (1), with a target price of $24.5, which is +200.25% compared to the current price. The earnings rating for AN2 Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AN2 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AN2 Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 8.39, ATR14 : 1.67, CCI20 : -67.70, Chaikin Money Flow : -0.35, MACD : -1.39, Money Flow Index : 48.04, ROC : 0.12, RSI : 38.27, STOCH (14,3) : 30.97, STOCH RSI : 0.77, UO : 36.91, Williams %R : -69.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AN2 Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary RatingStrong Buy
1.00
Strong Buy
1.00
-
0.00

AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

CEO:

Telephone: +1 650 331-9090

Address: 1800 El Camino Real, Menlo Park 94027, CA, US

Number of employees: 22

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

TipRanks News for ANTX

Thu, 12 May 2022 07:28 GMT AN2 Therapeutics, Inc. (ANTX) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits